Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Chong Kun Dang Pharmaceutical Corp
DalCor Pharmaceuticals Inc
NewAmsterdam Pharma BV
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
CKD-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalcetrapib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obicetrapib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CETP for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2020: DalCor announces dal-GenE trial continues with fil data expected in the first half of 2021
Jan 27, 2020: Dalcor announces Dal-gene trial to continue as planned following interim futility alysis
Dec 17, 2018: Dalcor announces completion of patient enrollment in Dal-gene, the first phase 3 precision medicine cardiovascular outcomes trial in corory heart disease
Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile
Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial
Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial
Mar 07, 2017: DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule
Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans
Aug 23, 2016: DalCor Announces Opening of Intertiol Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
Jun 08, 2015: DalCor Pharma licenses a late-stage investigatiol cardiovascular drug following major scientific discovery
Jun 03, 2015: Dezima Pharma’s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
Jan 12, 2015: A World First - Discovery of a persolized therapy for cardiovascular disease
Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
Pipeline by DalCor Pharmaceuticals Inc, H2 2020
Pipeline by NewAmsterdam Pharma BV, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
Discontinued Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020 (Contd..2), H2 2020